Az St-Jan Brugge-Oostende A.V. — Clinical Trial Site

183 Registered trials

74 Currently recruiting

Organisation

Az St-Jan Brugge-Oostende A.V.

Location

Brugge, Belgium

Identifier

ORG-100023348

Address

Ruddershove 10, 8000, Belgium

Departments

#1504: Rheumatology
#2001: Neurology
#3060: Cardiology
#7500: Neurologie
0504: Medische Oncologie
05605 Huisartsenwachtpost
2050 : Neurology
3060:Cardiology
3702; Reumatology
6043: Rheumatology
7001 : Neurology
7113: Laboratory
723: Hematologie
Afd. Hematologie
Anesthesia and Critical Care
Anesthesiology
BE10007: Hematology
Cardiologie - Campus Sint-Jan
Cardiology
Departement of Hematology
Department of Cardiology
Department of Hematology
Department of Urology
Dermatologie
Dermatology
Dienst Cardiologie
Dpeartment of Clinical Trials
Endocrinology
Fertiliteit
Gastro-enterology
Gastroenterology
Gynaecologie-Verloskunde
Haematology
Hematologie
Hematology
Hematology Department
Intensive Care
Internal Medicine / Endocrinology
Jan Cardiology - Patient Visits
Maag-, Darm- en leverziekten
Medical Oncology
N/A
NA
Nefrologie
Neonatal Intensive Care Unit
Neonatology
Neurology
Oncology
Oncology and /or Hematology
Ophthalmology
Paediatrics - paediatrics neurology
Pediatrics
Pijnkliniek
Pneumology
Radiotherapy
Radiotherapy-Oncology
Reumatologie
Rheumatology
Urologie
Urology
Valvular & structural heart disease, cardiomyopathies

Clinical trials at this site (183)

Search interface

A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 RELAPSE/REFRACTORY B-CELL LYMPHOMA. 4 2021-06-10
Open-label Phase 2 of tabelecleucel in Subjects with Epstein Barr Virus associated Diseases (EBVision) Recruiting

2024-516623-14-00 EBV+ primary imunodeficiency lymphoproliferative diseas 4 2021-03-17
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the i… Recruiting

2023-504417-67-00 Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiog 6 2020-12-22
GROINSS-V III Recruiting

2023-508722-99-00 Vulvar cancer 4 2020-11-19
Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting

2024-515625-29-00 Apnea of prematurity 5 2020-06-16
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting

2024-518568-11-00 Hematological malignancies confirmed histologically: - 4 2019-02-04
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Prostate Cancer 5 2019-01-08
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Part… Ended

2023-506146-23-00 Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the 4 2025-11-17
A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended

2023-505394-32-00 chronic graft versus host disease 5 2025-02-06
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Chronic hepatitis B infection 4 2025-01-15
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 2 (STOP-PN2) Ended

2024-511881-35-00 Prurigo Nodularis 5 2024-12-17
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended

2022-502168-19-00 chronic graft-versus-host disease 4 2024-10-22
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) w… Ended

2024-512023-37-00 Prostate cancer 4 2024-06-27
Treat-CMV Ended

2022-500714-25-01 congenital CMV infection 5 2024-06-19
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2024-06-17
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
A study to determine if ALXN2220 is effective, safe, and tolerable in adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Ended

2023-506669-70-00 Adults with Transthyretin Amyloid Cardiomyopathy (ATTR- 5 2024-04-30
Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial) Ended

2023-508166-15-00 Ulcerative colitis (UC), Inflammatory bowel disease typ 6 2024-04-29
Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil… Ended

2023-506029-12-00 Migraine 5 2024-04-03
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04